Express News | Carisma Therapeutics Appoints DR. Eugene P. Kennedy as Chief Medical Officer
ReutersMay 2 07:30 ET
Carisma Therapeutics Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and...
PR NewswireApr 24 17:05 ET
Carisma Therapeutics, Inc. (NASDAQ:CARM) Not Doing Enough For Some Investors As Its Shares Slump 33%
Carisma Therapeutics, Inc. (NASDAQ:CARM) shareholders won't be pleased to see that the share price has had a very rough month, dropping 33% and undoing the prior period's positive performance. The
Simply Wall StApr 24 06:20 ET
Buy Rating on Carisma Therapeutics: Pioneering CAR-M Therapies in Oncology and Fibrosis
TipRanksApr 23 14:25 ET
Analysts Are Bullish on These Healthcare Stocks: Neurocrine (NBIX), Carisma Therapeutics (CARM)
TipRanksApr 23 14:20 ET
Carisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Preclinical data highlights the potential of engineered macrophage cell therapy as a treatment for liver and lung fibrosis Novel Redirected Soluble Modulator technology has demonstrated the potentia
PR NewswireApr 22 16:35 ET
Buy Rating Affirmed: Promising Clinical Data and Strategic Shift Bolster Carisma Therapeutics' Outlook
TipRanksApr 12 01:36 ET
Promising Future for Carisma Therapeutics' Cancer Immunotherapy: A Buy Rating Analysis
TipRanksApr 11 20:45 ET
CARISMA Therapeutics Price Target Announced at $6.00/Share by BTIG
CARISMA Therapeutics Price Target Announced at $6.00/Share by BTIG
Dow JonesApr 11 12:29 ET
BTIG Sees Carisma Therapeutics as 'Undervalued', Starts Shares Coverage With Buy
InvestingApr 11 09:08 ET
Express News | Carisma Therapeutics Inc : Btig Initiates Coverage With Buy Rating ; Target Price $6
Moomoo 24/7Apr 11 07:58 ET
Analysts Offer Insights on Healthcare Companies: Carisma Therapeutics (CARM), Avidity Biosciences (RNA) and Vera Therapeutics (VERA)
TipRanksApr 11 06:40 ET
Buy Rating Affirmed on Carisma Therapeutics Amid Promising Early Research and Pipeline Potential
TipRanksApr 11 06:26 ET
Here's Why CARISMA THERAP (CARM) Is a Great 'Buy the Bottom' Stock Now
Yahoo FinanceApr 4 09:55 ET
Carisma Therapeutics to Present at Upcoming Conferences
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and...
PR NewswireApr 3 07:00 ET
CARISMA Therapeutics Is Maintained at Buy by HC Wainwright & Co.
CARISMA Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow JonesApr 2 09:01 ET
HC Wainwright & Co. Maintains Buy on CARISMA Therapeutics, Lowers Price Target to $9
HC Wainwright & Co. analyst Mitchell Kapoor maintains CARISMA Therapeutics (NASDAQ:CARM) with a Buy and lowers the price target from $11 to $9.
BenzingaApr 2 08:51 ET
CARISMA Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/02/2024 318.6% HC Wainwright & Co. $11 → $9 Maintains Buy 11/29/2023 411.63% HC Wainwright & Co. → $11
BenzingaApr 2 08:50 ET
Analysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (ALDX), Carisma Therapeutics (CARM) and Panbela Therapeutics (OtherPBLA)
TipRanksApr 2 06:20 ET
Carisma Therapeutics Q4 Net Loss Narrows, Revenue Rises; Plans Job Cuts in Q2 -- Shares Decline
Carisma Therapeutics (CARM) reported a Q4 net loss Monday of $0.52 per diluted share, narrower than a loss of $7.61 a year earlier. Analysts polled by Capital IQ expected a loss of $0.55. Revenue for
MT NewswiresApr 1 16:06 ET
No Data
No Data